NCT04889183CompletedPhase 3
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
Source: ClinicalTrials.gov · Last updated 22 Apr 2025
Brief summary (registry, in English)
Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide 2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD progression.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 125 (actual)
- First submitted
- 6 May 2021
- Start date
- 14 Mar 2022
- Primary completion date
- 28 May 2024
- Lead sponsor
- University Medical Center Groningen
- Diseases
- Obesity
- NCT number
- NCT04889183
- EudraCT number
- 2021-001247-27
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 125
- From 14 Mar 2022 to the primary completion date, 28 May 2024
- 13 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cardiovascular disease event in 3 months prior to enrollment
- Treatment with GLP-1 RA \< 4 weeks prior to screening
- Acute pancreatitis \< 180 days prior to screening
Other illness
- Diagnosis with type 1 or type 2 Diabetes
- Uncontrolled thyroid disease TSH\>6.0 mIU/L or \<0.4 mIU/L at screening
Lab values
- Hba1c ≥ 6.5% at screening
Other
- History or presence of chronic pancreatitis
- Females of child-bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures
Who the study is looking for
- Age ≥ 18 years
- Body Mass index ≥ 27 kg/m2
- Albuminuria ≥ 30 mg/g and ≤ 3500 mg/g
- eGFR ≥ 25 ml/min/1.73m2
- Stable renal function prior to entry into the study defined as no more than 30% eGFR change in 3 months prior to enrolment
- Signed Informed Consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Of Calgary Coordinator of this site? Confirm its status | Calgary | Canada | Unknown status |
| Division of Nephrology University Health Network, University of Toronto Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| University Hospital Erlangen Coordinator of this site? Confirm its status | Erlangen | Germany | Unknown status |
| University Hospital Wuerzburg Coordinator of this site? Confirm its status | Würzburg | Germany | Unknown status |
| Hospital Universitari de Bellvitge Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Vall d'Hebron University Hospital Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Hospital Da Costa Burela Coordinator of this site? Confirm its status | Lugo | Spain | Unknown status |
| Hospital Clínico Universitario Coordinator of this site? Confirm its status | Valencia | Spain | Unknown status |
| Dept Internal Medicine, division of Nephrology Hospital Group Twente Coordinator of this site? Confirm its status | Almelo | Netherlands | Unknown status |
| Rijnstate Coordinator of this site? Confirm its status | Arnhem | Netherlands | Unknown status |
| Martini Ziekenhuis Coordinator of this site? Confirm its status | Groningen | Netherlands | Unknown status |
| University Medical Center Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Unknown status |
| Isala Coordinator of this site? Confirm its status | Zwolle | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.